MISTRG6kitW41: Enhanced Engraftment in a Cytokine Humanized Patient-Derived Xenotransplantation Mouse Model
Baassiri A, Maziarz J, Blackburn H, Maul-Newby H, VanOudenhove J, Zhang X, Matthews M, Paul S, Liu W, Sefik E, Salomonis N, Grimes H, Flavell R, Halene S. MISTRG6kitW41: Enhanced Engraftment in a Cytokine Humanized Patient-Derived Xenotransplantation Mouse Model. Blood 2024, 144: 1815-1815. DOI: 10.1182/blood-2024-211908.Peer-Reviewed Original ResearchPeripheral blood-mobilized stem cellsAcute myeloid leukemiaProgression to secondary acute myeloid leukemiaHematopoietic stem cellsWeeks post-engraftmentSecondary acute myeloid leukemiaStudies of myelodysplastic syndromesMyelodysplastic syndromeCD34+ cellsEngraftment levelsPeripheral bloodBone marrowK micePost-engraftmentMouse modelNSG miceMDS samplesEngraftment of human hematopoietic stem cellsEnhanced engraftmentProgression to acute myeloid leukemiaHealthy donor peripheral bloodHuman CD45+ cellsHuman hematopoietic stem cellsAnalysis of CD34+ cellsPercentage of lymphoid cellsImmune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab
Bewersdorf J, Hasle V, Shallis R, Thompson E, De Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox B, Zeidan A. Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab. Blood 2024, 144: 4585. DOI: 10.1182/blood-2024-194929.Peer-Reviewed Original ResearchAcute myeloid leukemiaAnti-PD-L1 antibody durvalumabOverall response rateMyelodysplastic syndromeComplete responseBM aspiratesMyeloid leukemiaInternational Working GroupBone marrowMyelodysplastic syndromes treated with azacitidineAcute myeloid leukemia ptsWild-type acute myeloid leukemiaSecondary acute myeloid leukemiaResponse criteriaAnti-PD-L1Immune checkpoint inhibitorsTreated with azacitidineOutcomes of patientsAny-cause deathGeneration of neoantigensVariant allele frequencySusceptible to treatmentMarrow CRAdverse cytogeneticsCheckpoint inhibitors